Neu Health Joins Global Incubator Programme, Advancing Precision Neurology for Parkinson's and Dementia Care

• GIP acceptance builds on Neu's FDA clearance for Parkinson's tremor measurement and major U.S. health system pilots with entry into America's largest medical innovation hub

LONDON, Sept. 11, 2025 /PRNewswire/ -- Neu Health, a precision neurology platform for Parkinson's and dementia, today announced its selection for the Global Incubator Programme (GIP): USA HealthTech - Medical Devices. The six‑month programme is delivered by Innovate UK in partnership with Texas Medical Center Innovation (TMCi) with support from the Department for Business & Trade (DBT). The competitive program supports UK medical device and digital health companies expanding into the U.S. market through access to the world's largest medical complex in Houston, Texas.

Houston's Texas Medical Center treats 10 million patients annually across its 21 hospitals and research institutions. This massive healthcare ecosystem makes it the ideal launching point for Neu's U.S. expansion into neurological care. The timing is critical as Parkinson's affects over one million Americans with cases projected to grow 20% by 2030, while dementia impacts 6+ million nationwide. With neurologist shortages straining health systems, scalable solutions for brain care have become essential. Texas has also made brain health a strategic priority through initiatives like the Dementia Prevention Research Institute of Texas (DPRIT), which funds research into neurological disorders and supports the development of innovative technologies.

The selection comes on the heels of Neu's U.S. launch and FDA 510(k) clearance for its smartphone-based measurement tool for resting tremor in Parkinson's disease. The clearance covers the first known fully phone-based system, with no wearable or in-clinic hardware, for measuring motor symptoms in Parkinson's care. Neu is already piloting its platform at Cedars-Sinai and Mass General Brigham, with additional U.S. market expansions underway.

"The expertise and networks through the Global Incubator Programme at TMC give us the opportunity to reach the health systems and clinicians who are ready to move beyond reactive care," said Caroline Cake, CEO and co-founder of Neu Health. "Every day these tools aren't in the hands of families means more people are facing decline without support. This incubator accelerates our mission to change that."

Built on over a decade of Oxford University research and validated across NHS Trusts in the UK, Neu Health's platform transforms smartphone-based assessments into actionable clinical insights, helping clinicians detect neurological decline before traditional assessments. The technology enables continuous monitoring from home while integrating seamlessly into existing clinical workflows, addressing a critical gap as most patients wait six months or longer between neurology appointments.

Through GIP, Neu will leverage TMC Innovation's ecosystem to connect with clinical leaders, hospital systems, and investor networks within the world's largest medical complex. Participants also receive expert mentorship on U.S. regulatory strategy, commercialization, and market navigation. The program's curated connections to Houston's 1,760+ life sciences companies and investor networks create multiple pathways for partnerships and growth.

"We're entering the U.S. market at a moment when health systems are under pressure to manage neurological diseases more effectively," said Lorna Sharpe, Director of Business Operations at Neu Health. "GIP gives us the opportunity to work alongside the clinicians and researchers tackling those challenges head‑on."

The six-month program runs from September 2025 to March 2026, combining virtual incubation with on-site immersion in Houston. The Global Incubator Programme has proven successful for UK healthtech companies entering the U.S. market, with previous cohorts securing significant funding, clinical partnerships, and successful market entry.

About Neu Health

Neu Health is pioneering a new model of precision neurology for dementia and Parkinson's disease. Care is proactive, compassionate, and designed for the realities of everyday life. The company's approach is built on some of the most advanced longitudinal datasets in neurodegenerative disease, including the Oxford Parkinson's Disease Centre Discovery Cohort. Neu Health is supported by Oxford Science Enterprises, the university-linked science investor that scales companies founded on Oxford research. Its smartphone-based platform turns structured at-home assessments into actionable insights that help clinicians detect decline earlier and act before symptoms escalate. The technology analyzes speech, movement, and cognition in just minutes a day using trained models to generate predictive scores and digital biomarkers that inform treatment and care. Neu has received clearance from the United States Food and Drug Administration and works with leading health systems in the United Kingdom and the United States to expand access, ease workforce strain, and set a higher standard for neurological care.

To learn more, visit https://neu.health.

Media Contact:
[email protected] 

SOURCE Neu Health